Open Nav

Please submit your session questions in advance at

Vallon Pharmaceuticals

Vallon Pharmaceuticals Inc., headquartered in Philadelphia, is an emerging pharmaceutical company focused on the development of new medications to help patients with central nervous system (CNS) disorders.

The company’s lead product candidate is an abuse deterrent formulation of amphetamine immediate release (ADAIR) for the treatment of ADHD and Narcolepsy. There is substantial unmet need for abuse deterrent psychostimulants, given that 5 million adolescents and adults misuse Rx stimulants annually and over 40% of abusers/misusers do so by non-oral routes of administration, predominately by snorting.

The ADAIR program is phase III ready. Vallon will begin conducting human abuse liability clinical trials of ADAIR in 1Q 2019.

  • Date:Monday, February 11
  • Time:9:30 AM - 9:45 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23258
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Increase awareness of Vallon Pharmaceuticals, and identify and meet with potential investors
  • Company
  • Company HQ City:Philadelphia
  • Company HQ State:Pennsylvania
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$7.0 MM
  • Size of Last Investment Round:$3.0 MM
  • Previous and Current Investors:Adamas Fund; Arcturus Therapeutics; private high net worth investors
  • CEO/Top Company Official:David Baker
  • Year Founded:2018
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:ADAIR (Abuse Deterrent Amphetamine Immediate Release)
  • Development Phase of Primary Product:Phase I
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):N/A; not currently seeking licensing partners
David Baker
Vallon Pharmaceuticals